Eintrag weiter verarbeiten
Efficacy of systemic ganciclovir as a therapeutic strategy for cytomegalovirus‐associated anterior uveitis in immunocompetent patients
Gespeichert in:
Personen und Körperschaften: | , , , , |
---|---|
Titel: |
Efficacy of systemic ganciclovir as a therapeutic strategy for cytomegalovirus‐associated anterior uveitis in immunocompetent patients |
In: | Acta Ophthalmologica, 87, 2009, s244, S. 0-0 |
veröffentlicht: |
Wiley
|
Umfang: | 0-0 |
ISSN: |
1755-375X 1755-3768 |
DOI: | 10.1111/j.1755-3768.2009.2266.x |
Zusammenfassung: | <jats:title>Abstract</jats:title><jats:p> <jats:bold>Purpose</jats:bold> Cytomegalovirus (CMV)‐associated anterior uveitis is a newly recognized entity that accounts for half of patients with Posner‐Schlossman syndrome. To date, the therapeutic management of these patients remains controversial. The aim of this study was to assess the efficacy of systemic Ganciclovir as a treatment for PCR‐proven CMV‐associated hypertensive anterior uveitis.</jats:p><jats:p> <jats:bold>Methods</jats:bold> Retrospective interventional study of 27 consecutive patients treated in a single centre between 2002 and 2008. Main outcome measures included intraocular pressure (IOP) and anterior chamber inflammation.</jats:p><jats:p> <jats:bold>Results</jats:bold> All patients responded to systemic Ganciclovir, with mean IOP dropping from 32 to 14 mmHg (p<0,05). Relapses occurred in 50% of cases within one year from the first antiviral course. Repeated treatment allowed control of the disease in 75% of cases (follow‐up range: 12‐78 months).</jats:p><jats:p> <jats:bold>Conclusion</jats:bold> Ganciclovir is effective but remains a suspensive therapeutic strategy.</jats:p> |
Format: | E-Article |
Quelle: | Wiley (CrossRef) |
Sprache: | Englisch |